sizofiran has been researched along with Experimental Hepatoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aleem, E; Baddour, N; Daba, A; El-Saadani, M; Mansour, A | 1 |
| Hashimoto, J; Kakuta, H; Kano, Y | 1 |
2 other study(ies) available for sizofiran and Experimental Hepatoma
| Article | Year |
|---|---|
Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Proliferation; Female; Immunohistochemistry; Liver Neoplasms, Experimental; Mammary Neoplasms, Experimental; Mice; Proliferating Cell Nuclear Antigen; Receptors, Estrogen; Schizophyllum; Sizofiran; Survival Analysis; Tamoxifen | 2012 |
Augmentation of the antitumor effect of adoptive immunotherapy by in vivo sensitization of EL-4 lymphoma and pre-treatment with sizofiran.
Topics: Adjuvants, Immunologic; Animals; Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Humans; Immunotherapy, Adoptive; Killer Cells, Lymphokine-Activated; Liver Neoplasms, Experimental; Lymphoma; Mice; Mice, Inbred C57BL; Mitomycin; Sizofiran; Spleen; Splenic Neoplasms | 1998 |